AURA3 trial: does Tagrisso (osimertinib) have the potential to become the new standard of care for second-line treatment of patients with EGFR T790M mutation-positive locally advanced or metastatic NSCLC
| Image |  |
|---|---|
| Description | scientific article published on 01 December 2016 |
| Author/s |
author: Vassiliki Papadimitrakopoulou |
| Publication date | December 1, 2016 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |